Showing 1,061 - 1,080 results of 1,220 for search '"Peking"', query time: 0.07s Refine Results
  1. 1061

    A Novel Risk Score Model for the Differential Diagnosis of Type 2 Diabetic Nephropathy: A Multicenter Study by Yuetong Zhao, Lin Liu, Li Zuo, Xianghai Zhou, Song Wang, Hongwei Gao, Feng Yu, Xiaomei Zhang, Mi Wang, Ling Chen, Rui Zhang, Fang Zhang, Shuhong Bi, Qiong Bai, Jiaxiang Ding, Qinghua Yang, Sixu Xin, Sanbao Chai, Min Chen, Junqing Zhang

    Published 2023-01-01
    “…A total of 678 T2D patients who had undergone renal biopsy in four affiliated hospitals of Peking University were consecutively enrolled. Patients were assigned to the DN group and NDKD group according to histopathological results. …”
    Get full text
    Article
  2. 1062
  3. 1063
  4. 1064
  5. 1065
  6. 1066
  7. 1067
  8. 1068
  9. 1069
  10. 1070
  11. 1071
  12. 1072
  13. 1073
  14. 1074
  15. 1075
  16. 1076

    The Prognostic Value of Peripheral Blood Inflammatory Markers in Hepatocellular Carcinoma Treated with Lenvatinib Combined with PD-1 Inhibitors by Xin Y, Liu N, Peng G, Huang X, Cao X, Zhou X

    Published 2025-01-01
    “…Yujing Xin,1 Ning Liu,2 Gang Peng,3 Xiaoyu Huang,3 Xiaojing Cao,3 Xiang Zhou3 1Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, People’s Republic of China; 2School of Software, Shandong University, Jinan, Shandong, 250101, People’s Republic of China; 3National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People’s Republic of ChinaCorrespondence: Xiang Zhou, Email zhou.xiang@yeah.netPurpose: To investigate the prognostic value of inflammatory indexes based on peripheral blood cells in unresectable hepatocellular carcinoma (HCC) patients treated with Lenvatinib combined with PD-1 inhibitors.Methods: This study retrospectively collected baseline inflammatory indexes from HCC patients received Lenvatinib and PD-1 inhibitor-based combination therapy at the Cancer Hospital of the Chinese Academy of Medical Sciences between October 2018 and October 2021. …”
    Get full text
    Article
  17. 1077
  18. 1078
  19. 1079

    Multicentre, prospective, randomised controlled trial to evaluate hexaminolevulinate photodynamic therapy (Cevira) as a novel treatment in patients with high-grade squamous intraep... by Fei Chen, Jinghe Lang, Peter Hillemanns, Youzhong Zhang, Zoltán Novák, Long Sui, Ling Han, Christian Dannecker, Ctirad Mokráš, Zhixue You

    Published 2022-06-01
    “…All patients in the Cevira group will be enrolled in an open, long-term extension study for 6 months to collect additional efficacy and safety data (study extension endpoints).Ethics and dissemination The study was approved by the ethics committee of the Peking Union Medical College Hospital and Hannover Medical University, Germany. …”
    Get full text
    Article
  20. 1080